This trial is examining a new anti-cancer medication for non-small cell lung cancer called tislelizumab. The main outcome that will be measured is how long it takes for the cancer to start growing again. This study is recruiting across the United States.
Non-small cell lung cancer (NSCLC) can be difficult to treat. Chemotherapy before or after surgery to remove the tumor are often used. However, in some cases, this treatment is not enough. Tislelizumab is a new medication which targets the immune system. This medication has been tested for safety, but it is not known how effective it is in humans.
This trial is evaluating the effectiveness of tislelizumab with chemotherapy before and after surgery in patients with NSCLC. The main outcome that will be measured is how long it takes for the tumor to start growing again.
Who are they looking for?
This trial is recruiting 840 patients with stage III NSCLC that cannot be surgically removed. Patients must have good organ function and should have tests done for the EGFR or ALK genes.
Patients cannot have previously had allergies to immunotherapy before. This must be the first occurrence of the cancer. Patients cannot have had an organ transplant. Patients cannot have heart, lung conditions, infections, or other uncontrolled diseases.
How will it work
Patients will be split into three groups. Group one will receive treatment with tislelizumab and platinum-based chemotherapy for six weeks, followed by treatment with tislelizumab alone. Group two will receive a placebo and platinum-based chemotherapy followed by treatment with tislelizumab alone. Group three will receive a placebo and platinum-based chemotherapy followed by treatment with a placebo alone.
Patients will be followed up for treatment response, survival and side effects up to 5 years.